Freyr is a Global Regulatory Solutions and Services company, focusing on the entire Regulatory value-chain ranging from Regulatory Strategy, Intelligence, Dossiers, Submissions to post approval maintenance, Labeling, Artwork Change Management for Pharmaceutical, Generics, Medical Device, biotechnology, Biosimilar, Consumer Healthcare, Cosmetic companies across the globe.
-
154 Publicações
-
36 fotos
-
1 Vídeos
-
Medical Device Regulatory Consulting
-
Male
-
31/07/1991
-
Seguido por 0 pessoas
Atualizações Recentes
-
0 Comentários 0 Compartilhamentos 48 Visualizações 0 AnteriorFaça Login para curtir, compartilhar e comentar!
-
0 Comentários 0 Compartilhamentos 48 Visualizações 0 Anterior
-
0 Comentários 0 Compartilhamentos 40 Visualizações 5 0 Anterior
-
What is a Biowaiver under JFDA GuidelinesA biowaiver under the Jordan Food and Drug Administration (JFDA) guidelines is a Regulatory approval that allows a pharmaceutical manufacturer to skip in vivo bioequivalence (BE) studies in human volunteers. Instead of testing the drug in humans to prove it performs the same as the innovator (reference) product, the JFDA allows the use of comparative in vitro dissolution testing as an...0 Comentários 0 Compartilhamentos 58 Visualizações 0 Anterior
-
What Is the 60-Day Silent Approval Mechanism for Clinical Trials in ChinaChina has become a major destination for global clinical development, and one reason is its 60-day silent approval mechanism for clinical trials. Introduced as part of China’s drug Regulatory reforms and outlined under the National Medical Products Administration (NMPA) framework, this mechanism allows sponsors to begin clinical trials if regulators do not raise objections within 60...0 Comentários 0 Compartilhamentos 43 Visualizações 0 Anterior
-
Top 5 Pitfalls When Registering Medicines in AustraliaMarket Context Australia remains a highly attractive pharmaceutical market due to its strong regulatory framework and global credibility. However, registering medicinal products with the Therapeutic Goods Administration (TGA) requires more than just dossier submission. In 2026, sponsors are facing increasing scrutiny around submission quality, GMP compliance, and lifecycle...0 Comentários 0 Compartilhamentos 43 Visualizações 0 Anterior
-
Global Drug Registration 2026: Comparing TGA, FDA & EMA Regulatory PathwaysMarket Context As pharmaceutical companies expand globally, understanding regional regulatory pathways has become essential for faster market access and lifecycle efficiency. In 2026, sponsors seeking approvals across Australia, the US, and Europe must navigate the distinct requirements of the Therapeutic Goods Administration (TGA), U.S. Food and Drug Administration (FDA), and European...0 Comentários 0 Compartilhamentos 34 Visualizações 0 Anterior
-
Japan Drug Approval TimelinesFor pharmaceutical companies planning global launches, understanding drug approval timelines across regions is critical. While Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) is aligned with global standards through ICH, approval timelines in Japan can differ significantly from those of the FDA (US) and EMA (EU). How Do PMDA Timelines Compare? In general: FDA is often...0 Comentários 0 Compartilhamentos 36 Visualizações 0 Anterior
-
China Pharma Trade & Market Access TrendsChina continues to strengthen its position as a global pharmaceutical manufacturing, biotechnology, and healthcare innovation hub. Evolving trade agreements, Regulatory reforms, and supply chain strategies are creating new opportunities and challenges for global pharmaceutical companies seeking market entry and expansion in China. As pharmaceutical supply chains become increasingly globalized,...0 Comentários 0 Compartilhamentos 43 Visualizações 0 Anterior
-
Innovative Drug Development in China | NMPA GuideChina’s pharmaceutical landscape is rapidly evolving, making the country one of the most strategic destinations for innovative drug development, biotechnology investments, and pharmaceutical market expansion. With continuous National Medical Products Administration (NMPA) reforms, accelerated approval pathways, and increased focus on innovative therapies, global pharmaceutical and biotech...0 Comentários 0 Compartilhamentos 45 Visualizações 0 Anterior
-
China eCTD Compliance & NMPA Submission GuideAs China continues modernizing its pharmaceutical Regulatory systems, eCTD compliance has become increasingly important for pharmaceutical companies seeking successful NMPA submissions and faster Regulatory approvals. Organizations preparing China Regulatory submissions must ensure their dossiers meet evolving technical, operational, and compliance expectations. Why China eCTD Compliance...0 Comentários 0 Compartilhamentos 45 Visualizações 0 Anterior
-
China Drug Regulatory Reforms | NMPA UpdatesChina’s pharmaceutical Regulatory environment continues evolving rapidly as the National Medical Products Administration (NMPA) strengthens innovation-focused policies, accelerated approval pathways, lifecycle supervision, and compliance oversight. These reforms are reshaping how pharmaceutical and biotechnology companies approach product registration, market entry, pharmacovigilance, and...0 Comentários 0 Compartilhamentos 43 Visualizações 0 Anterior
Mais Stories